{"id":508185,"date":"2020-09-23T19:22:02","date_gmt":"2020-09-23T19:22:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=508185"},"modified":"2020-09-23T19:22:02","modified_gmt":"2020-09-23T19:22:02","slug":"benign-prostatic-hyperplasia-bph-epidemiology-forecast-to-2030-bph-epidemiology-forecast-to-2030-by-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/benign-prostatic-hyperplasia-bph-epidemiology-forecast-to-2030-bph-epidemiology-forecast-to-2030-by-delveinsight_508185.html","title":{"rendered":"Benign Prostatic Hyperplasia (BPH) Epidemiology Forecast to 2030 | BPH Epidemiology Forecast to 2030 by DelveInsight"},"content":{"rendered":"<div style=\"float:right; width:250px;\" class=\"quotes\">\n<div>DelveInsight Business Research LLP<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">DelveInsight&#8217;s &#8216;Benign prostatic hyperplasia (BPH) &#8211; Epidemiology Forecast to 2030&#8217; report delivers an in-depth understanding of the disease, historical and forecasted Benign prostatic hyperplasia (BPH) epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.<\/p>\n<\/div>\n<p style=\"text-align: justify;\">DelveInsight has introduced a new&nbsp;Report on<strong>&nbsp;&ldquo;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/benign-prostatic-hyperplasia-bph-epidemiology-forecast\">Benign prostatic hyperplasia (BPH) Epidemiology Forecast to 2030<\/a>&rdquo;<\/strong><\/p>\n<p style=\"text-align: justify;\">DelveInsight&rsquo;s&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/benign-prostatic-hyperplasia-bph-epidemiology-forecast\">&lsquo;<strong>Benign prostatic hyperplasia (BPH) Epidemiology Forecast<\/strong>&lsquo;<\/a>&nbsp;report delivers an in-depth understanding of the disease, historical and forecasted Benign prostatic hyperplasia (BPH) epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.<\/p>\n<p style=\"text-align: justify;\"><strong>Key Highlights from report are:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>As per an article by Boyle et al., titled &ldquo;Epidemiology of Benign Prostatic Hyperplasia: Current Perspectives,&rdquo; half of the men over 60 may have symptoms compatible with BPH, and that up to 60% of men over 60 may have hypertension.<\/li>\n<li>The prevalence of BPH was found to be 19.9% for men of age 40&ndash;59; 37.0% for 60&ndash;69; 50.5% for 70&ndash;79; and 58.2% for &ge;80.<\/li>\n<li>The age-specific prevalence was 14.2%, 17.6%, and 23.3% for age groups 50&ndash;59, 60&ndash;64, and &ge;65 years, respectively.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/benign-prostatic-hyperplasia-bph-epidemiology-forecast\">Request for Sample Pages: &nbsp;https:\/\/www.delveinsight.com\/sample-request\/benign-prostatic-hyperplasia-bph-epidemiology-forecast<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Benign Prostatic Hyperplasia (BPH)<\/strong>&nbsp;is a noncancerous condition in men in which the prostate gland is enlarged. BPH is also called benign prostatic hypertrophy or benign prostatic obstruction.<\/p>\n<p style=\"text-align: justify;\">The prostate goes through two main growth periods as a man ages. The first occurs early in puberty when the prostate doubles in size. The second phase of growth begins around age 25 and continues during most of a man&rsquo;s life. BPH often occurs with the second growth phase.<\/p>\n<p style=\"text-align: justify;\">The enlarged prostate gland presses against and pinches the urethra. The bladder wall becomes thicker. Ultimately the bladder may weaken and lose the ability to empty completely. The narrowing of the urethra and urinary retention causes many of the problems associated with BPH.<\/p>\n<p style=\"text-align: justify;\">Need of frequent urination is a common symptom. Other symptoms include the feeling of full bladder even after urination, a week flow of urine, stop-start urination, difficulty in starting urination, and needing to get up frequently in the night to urinate.<\/p>\n<p style=\"text-align: justify;\">The cause of BPH is not well understood; however, it is most common in old men. As BPH does not develop in men whose testicles were removed before puberty, some researchers believe factors related to aging and the testicles are the underlying causes.<\/p>\n<p style=\"text-align: justify;\">Researchers also believe that a high proportion of estrogen within the prostate stimulates the activity of prostate cell growth factors. Another theory suggests that dihydrotestosterone (DHT) that plays a role in prostate development and growth may be the cause as it is found that men who do not produce DHT do not develop BPH.<\/p>\n<p style=\"text-align: justify;\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/benign-prostatic-hyperplasia-bph-market\">Request for Sample Pages: https:\/\/www.delveinsight.com\/sample-request\/benign-prostatic-hyperplasia-bph-market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>According to the study by Lee et al., BPH is more common in older males as compared to those below 40 years.<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Table of Contents<\/strong><\/p>\n<ol style=\"text-align: justify;\">\n<li><strong>Key Insights<\/strong><\/li>\n<li><strong>Executive Summary of Benign prostatic hyperplasia (BPH)<\/strong><\/li>\n<li><strong>Benign prostatic hyperplasia (BPH): Disease Background and Overview<\/strong><\/li>\n<li><strong>Patient Journey<\/strong><\/li>\n<li><strong>Epidemiology and Patient Population<\/strong><\/li>\n<li><strong>Treatment Algorithm, Current Treatment, and Medical Practices<\/strong><\/li>\n<li><strong>KOL Views<\/strong><\/li>\n<li><strong>Unmet Needs<\/strong><\/li>\n<li><strong>Appendix<\/strong><\/li>\n<li><strong>DelveInsight Capabilities<\/strong><\/li>\n<li><strong>Disclaimer<\/strong><\/li>\n<li><strong>About DelveInsight<\/strong><\/li>\n<\/ol>\n<p style=\"text-align: justify;\"><strong>Request for Detailed TOC of the report:&nbsp;<\/strong>https:\/\/www.delveinsight.com\/sample-request\/benign-prostatic-hyperplasia-bph-epidemiology-forecast<\/p>\n<p style=\"text-align: justify;\"><span><strong>Related Reports<\/strong><\/span><\/p>\n<p style=\"text-align: justify;\"><strong>Benign prostatic hyperplasia (BPH) &ndash; Pipeline Insights, 2020<\/strong><\/p>\n<p style=\"text-align: justify;\">&ldquo;<strong>Benign prostatic hyperplasia (BPH) Pipeline Insight, 2020<\/strong>&rdquo; report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the&nbsp;<strong>Benign prostatic hyperplasia (BPH)&nbsp;<\/strong>market.<\/p>\n<p style=\"text-align: justify;\"><strong>Benign prostatic hyperplasia (BPH)- Market Insight, Epidemiology and Market Forecast -2030<\/strong><\/p>\n<p style=\"text-align: justify;\">DelveInsight&rsquo;s &ldquo;<strong>Benign prostatic hyperplasia (BPH) &ndash; Market Insights, Epidemiology, and Market Forecast-2030&Prime;<\/strong>&nbsp;report delivers an in-depth understanding of the Benign prostatic hyperplasia (BPH), historical and forecasted epidemiology as well as the Benign prostatic hyperplasia (BPH) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/p>\n<p style=\"text-align: justify;\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/dravet-syndrome-market\">Contact us:<\/a><\/strong><br \/><strong>Shruti Thakur<br \/>info@delveinsight.com<br \/>+91-9650213330<\/strong><\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56431.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Kritika Rehani<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=benign-prostatic-hyperplasia-bph-epidemiology-forecast-to-2030-bph-epidemiology-forecast-to-2030-by-delveinsight\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 9193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> Nevada<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=benign-prostatic-hyperplasia-bph-epidemiology-forecast-to-2030-bph-epidemiology-forecast-to-2030-by-delveinsight\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>DelveInsight Business Research LLP DelveInsight&#8217;s &#8216;Benign prostatic hyperplasia (BPH) &#8211; Epidemiology Forecast to 2030&#8217; report delivers an in-depth understanding of the disease, historical and forecasted Benign prostatic hyperplasia (BPH) epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/benign-prostatic-hyperplasia-bph-epidemiology-forecast-to-2030-bph-epidemiology-forecast-to-2030-by-delveinsight_508185.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,435,406,423,404],"tags":[],"class_list":["post-508185","post","type-post","status-publish","format-standard","hentry","category-Business","category-Europe","category-Pharmaceuticals-Biotech","category-Professional-Services","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/508185","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=508185"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/508185\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=508185"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=508185"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=508185"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}